Publications by authors named "Yusuke Minematsu"
Article Synopsis
- * In the U.S., apheresis mainly utilizes centrifugal separation, while Japan prefers a membrane separation method, complicating the application of ASFA guidelines in Japanese practice due to differing disease targets and treatment approaches.
- * A group of specialists in various medical fields collaborated to create a comprehensive guideline for apheresis in Japan, formatted as a user-friendly worksheet to assist medical professionals with the therapy, and emphasizing the need for regular updates to keep pace with advancing medical
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020), a Japanese-specific set of clinical practice guidelines for sepsis and septic shock created as revised from J-SSCG 2016 jointly by the Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine, was first released in September 2020 and published in February 2021. An English-language version of these guidelines was created based on the contents of the original Japanese-language version. The purpose of this guideline is to assist medical staff in making appropriate decisions to improve the prognosis of patients undergoing treatment for sepsis and septic shock.
View Article and Find Full Text PDFArticle Synopsis
- - The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2020 (J-SSCG 2020) were developed to help healthcare professionals effectively treat sepsis and septic shock, building on the previous guidelines from 2016.
- - The guidelines cover 22 areas including important new topics such as patient-centered care and ICU-acquired weakness, and detail 118 clinical questions that address various aspects of sepsis management.
- - In creating these guidelines, a diverse group of 226 medical professionals used the GRADE method for recommendations, resulting in 79 GRADE-based recommendations and 5 Good Practice Statements.
Background: Recent studies have shown that fibroblast growth factor-23 (FGF-23) is elevated not only in chronic kidney disease (CKD), but also in acute illnesses such as acute kidney injury, septic shock, and acute heart failure. FGF-23 would be not only a simple biomarker but also a direct toxic factor in acute illness. Therefore, lowering circulating FGF-23 levels in clinical practice would be an exciting and valuable interventional strategy.
View Article and Find Full Text PDFBackground: The most frequent cause of acute kidney injury (AKI) needing renal replacement therapy is sepsis, with the prognosis of patients with septic AKI worse than for other causes of this disease. Recent studies have shown that fibroblast growth factor-23 (FGF-23) levels, one of the phosphaturic and prognostic factors in chronic kidney disease, are also elevated in patients with AKI and correlate with an increased risk of death or a need for dialysis. In addition, FGF-23 was found to inhibit the extra-renal synthesis of 1,25-dihydroxyvitamin D by human monocytes.
View Article and Find Full Text PDFDisseminated intravascular coagulation (DIC) and multiple organ failure often occur via the crosstalk between inflammation and coagulation, which is mediated by High Mobility Group Box 1 (HMGB1). In septic shock, Polymyxin-B direct hemoperfusion (PMX-DHP) ameliorates hemodynamics by endogenous cannabinoid adsorption and improves pulmonary oxygenation by indirect cytokine reduction through the adsorption of activated mononuclear cells. However, PMX-DHP has no direct effect on HMGB1 circulating in the plasma.
View Article and Find Full Text PDF